genu
flaviviru
famili
flavivirida
compris
sever
pathogen
includ
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
tickborn
enceph
viru
tbev
japanes
enceph
viru
jev
flavivirus
pathogen
man
transmit
human
bite
mosquito
tick
incid
geograph
distribut
four
distinct
denv
serotyp
vector
increas
dramat
denv
caus
million
infect
annual
mainli
southeast
asia
latin
america
infect
viru
may
develop
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
increas
diseas
sever
associ
preexist
heterolog
denv
antibodi
phenomenon
describ
antibodydepend
enhanc
ade
infect
antibodi
found
enhanc
viral
entri
cell
alter
antivir
immun
respons
lead
increas
viru
particl
product
subsequ
immun
activ
homolog
reinfect
antibodi
believ
neutral
infect
viru
provid
lifelong
protect
diseas
develop
intriguingli
howev
heterolog
reinfect
crossreact
antibodi
implic
enhanc
viral
replic
lead
higher
infect
cell
mass
increas
viral
burden
neither
vaccin
specif
antivir
therapi
avail
also
case
yfv
togeth
denv
lead
caus
hemorrhag
fever
worldwid
although
highli
efficaci
vaccin
avail
furthermor
vectorcontrol
strategi
success
elimin
yfv
falter
therebi
lead
reemerg
diseas
world
health
organ
current
estim
case
yellow
fever
annual
occur
africa
result
death
per
year
case
flavivirus
antivir
drug
avail
treatment
yfv
infect
glycopeptid
antibiot
ie
teicoplanin
eremomycin
vancomycin
use
treatment
gramposit
bacteri
infect
synthet
modifi
glycopeptid
antibiot
sgpa
report
endow
vitro
antivir
activ
retro
corona
virus
human
immunodefici
viru
hiv
shown
semisynthet
glycopeptid
aglycon
potenti
interfer
viral
entri
process
mechan
deglycosyl
sgpa
exert
antivir
activ
virus
remain
unclear
recent
demonstr
teicoplanin
aglycon
analogu
inhibit
replic
hepat
c
viru
hcv
interf
intracellular
replic
viru
report
also
exert
vitro
antiflaviviru
activ
surprisingli
interf
earli
stage
viral
replic
cycl
effect
figur
vitro
infect
select
flavivirus
evalu
cpereduct
assay
viru
yield
reduct
assay
inhibit
cpe
format
dosedepend
manner
figur
concentr
prove
cytotox
assess
microscop
mtspm
method
cpe
format
complet
inhibit
although
reduc
viabil
uninfect
host
cell
cultur
concentr
assess
mt
method
cytostat
effect
note
concentr
cell
count
coulter
counter
denv
figur
panel
c
yfv
figur
panel
f
protein
express
respect
e
complet
inhibit
concentr
antivir
effect
confirm
viru
yield
reduct
assay
valu
ribavirin
includ
refer
molecul
figur
addit
inhibit
replic
tickborn
enceph
viru
west
nile
viru
japanes
enceph
viru
murin
flaviviru
modoc
viru
modv
tabl
timeofdrugaddit
experi
carri
obtain
first
indic
stage
viral
replic
cycl
exert
antivir
activ
ad
time
infect
sever
time
point
infect
h
pi
luciferas
activ
viral
antigen
express
denv
viral
rna
content
analyz
compar
untreat
infect
cell
addit
compound
time
infect
result
nearli
complet
inhibit
viral
replic
viral
antigen
express
figur
fail
effici
inhibit
denv
infect
ad
h
later
infect
figur
panel
yfv
protect
activ
alreadi
lost
ad
infect
cultur
min
pi
later
figur
thu
interfer
earliest
stage
viral
replic
cycl
studi
whether
inhibitori
effect
result
direct
virucid
activ
incub
h
presenc
absenc
andor
rnase
viral
rna
amplifi
viru
sampl
incub
contain
compar
amount
viral
rna
sampl
incub
molecul
demonstr
destroy
viral
particl
data
shown
contrast
viru
sampl
incub
proteinas
k
viral
rna
longer
detect
confirm
exert
antivir
effect
earli
stage
viral
replic
entryuptak
later
stage
effect
molecul
denv
subgenom
replicon
replic
encod
nonstructur
viral
protein
studi
inhibit
replic
denv
subgenom
replicon
wherea
replic
inhibitor
ribavirin
data
shown
indic
exert
antivir
activ
target
one
structur
protein
observ
corrobor
data
obtain
timeofdrugaddit
studi
microscopybas
bind
fusion
assay
use
didlabel
viru
next
employ
studi
whether
interfer
viru
bind
andor
entri
host
cell
didlabel
denv
virion
influenc
specif
infect
viru
abil
didlabel
virion
bind
cell
surfac
receptor
increas
concentr
assess
highli
permiss
cell
untreat
cell
averag
didlabel
viru
particl
detect
addit
markedli
reduc
number
bound
viru
particl
cell
dosedepend
manner
figur
concentr
inhibit
viruscel
bind
result
demonstr
act
prevent
viruscel
bind
next
investig
whether
addit
effect
membran
fusion
capac
viru
end
cell
infect
didlabel
particl
presenc
differ
concentr
rel
extent
viru
fusion
estim
measur
total
fluoresc
signal
per
imag
field
membran
fusion
activ
denv
effici
reduc
cell
treat
refer
control
ammonium
chlorid
chlorpromazin
figur
markedli
impair
membran
fusion
activ
denv
figur
effect
like
ascrib
low
bind
effici
virion
cell
presenc
statist
signific
ad
effect
measur
inhibit
membran
fusion
activ
compar
effect
bind
figur
observ
prevent
viru
bind
cell
surfac
prompt
us
evalu
whether
also
exert
antivir
effect
toward
denv
particl
preopson
antibodi
end
infecti
properti
denv
particl
preopson
enhanc
concentr
anti
mab
determin
presenc
increas
concentr
experiment
condit
cell
infect
denv
absenc
mab
wherea
presenc
enhanc
concentr
anti
mab
cell
infect
denv
infect
anti
mab
opson
denv
particl
markedli
reduc
presenc
figur
confirm
effect
observ
antibodyspecif
effect
two
anti
mab
map
e
domain
iii
e
domain
iii
respect
evalu
agreement
result
obtain
anti
mab
infect
denvimmun
complex
form
anti
significantli
reduc
presenc
respect
data
shown
addit
target
viral
enzym
indispens
replic
interfer
viru
entri
step
may
attract
therapeut
strategi
flaviviru
entri
host
cell
consist
sever
dynam
event
includ
viru
attach
receptormedi
endocytosi
phdepend
membran
fusion
viru
uncoat
step
potenti
serv
target
inhibit
viru
life
cycl
denv
e
protein
repres
attract
target
inhibit
denv
entri
sinc
play
crucial
role
bind
viru
particl
host
cell
receptor
fusion
viral
membran
target
membran
polyanion
substanc
plant
lectin
amongst
other
shown
capabl
inhibit
first
step
flaviviru
replic
cycl
ie
bind
host
cell
polyanion
compound
act
heparin
sulphatemimet
substanc
interf
interact
e
glycoprotein
cellular
heparan
sulphat
receptor
lectin
particular
sugarbind
specif
report
prevent
interact
e
glycoprotein
cellular
receptor
dcsign
addit
interf
bind
target
e
protein
may
also
affect
fusion
viru
particl
cellular
membran
virtual
screen
employ
identifi
molecul
interact
pocket
e
protein
although
method
seem
promis
screen
still
need
refin
addit
recent
report
analogu
antibiot
doxorubicin
exert
antiflaviviru
activ
prevent
entri
viru
like
via
interact
pocket
report
antidenv
activ
aglycon
deriv
antibiot
teicoplanin
inhibit
replic
denv
also
flavivirus
albeit
differ
effici
includ
yfv
wnv
jev
particular
tbev
timeofdrugaddit
studi
reveal
compound
exert
antivir
activ
time
infect
inhibit
bind
viru
host
cell
support
observ
contrast
replic
inhibitor
ribavirin
effect
denv
subgenom
replicon
replic
henc
inhibit
intracellular
replic
machineri
viru
besid
microscopybas
bind
fusion
assay
use
didlabel
particl
reveal
inhibit
denv
infect
prevent
bind
viru
host
cell
observ
may
point
interact
e
protein
howev
studi
need
elucid
specif
antivir
target
inhibit
direct
virucid
effect
exclud
well
earlier
identifi
inhibitor
viral
infect
human
immunodefici
viru
felin
human
coronaviru
hepat
c
viru
mechan
action
hiv
coronavirus
ascrib
like
effect
entri
contrast
rather
pronounc
vitro
activ
hcv
caus
inhibitori
effect
intracellular
viral
replic
remark
given
fact
flavivirus
hcv
belong
famili
flavivirida
one
molecul
inhibit
replic
close
relat
virus
affect
two
entir
differ
stage
replic
cycl
interest
exampl
anoth
antivir
agent
inhibit
replic
two
differ
virus
via
differ
mechan
action
target
cellular
factor
cyclophilin
bind
molecul
cyclosporin
relat
analogu
nonimmunosuppress
molecul
inhibit
activ
cyclophilin
essenti
cofactor
replic
hiv
hcv
inhibitori
effect
hiv
replic
caus
interact
matrix
protein
thu
encapsid
process
wherea
effect
hcv
mediat
via
cistran
isomeris
hcv
requir
viral
rna
replic
interestingli
flavivirus
studi
elicit
highest
antivir
activ
tbev
prove
least
activ
wnv
yet
explan
differ
respons
differ
flavivirus
order
identifi
molecular
target
least
target
viral
protein
attempt
made
gener
drugresist
variant
howev
far
abl
select
drugresist
variant
even
follow
passag
presenc
suboptim
concentr
molecul
indic
high
barrier
resist
current
continu
effort
select
drugresist
variant
yet
exclud
inhibit
entri
process
via
interact
cellular
target
would
mean
flavivirus
suscept
use
cellular
factor
entri
target
interact
host
cell
membran
disturb
flaviviru
entri
process
also
exclud
howev
mechan
may
difficult
explain
entri
process
close
relat
hcv
affect
molecul
altogeth
precis
mechan
inhibit
bindingentri
process
remain
elucid
found
also
interfer
antibodymedi
cell
entri
denv
particl
ade
thought
play
pivot
role
exacerb
denvinduc
diseas
secondari
infect
dhf
dss
henc
drug
properti
like
could
particular
interest
intervent
strategi
ad
preform
virusantibodi
complex
also
shown
result
condit
antivir
effect
result
suggest
interfer
denv
infect
direct
bind
viru
receptor
sinc
antibodymedi
cell
entri
denv
facilit
fcreceptor
viru
receptor
inde
result
strengthen
hypothesi
bind
host
cell
receptor
viru
howev
inhibitori
effect
exert
earli
sinc
molecul
wash
away
ade
experi
hr
infect
particular
mechan
inhibit
ade
remain
elucid
conclus
report
teicoplanin
aglycon
analogu
exert
broadspectrum
activ
flavivirus
vitro
interfer
earli
step
viral
replic
cycl
bindingentri
includ
antibodi
depend
enhanc
denv
infect
insight
precis
mechan
exert
antivir
activ
may
allow
ration
design
potent
select
inhibitor
flaviviru
entri
denv
serotyp
new
guinea
c
ngc
kindli
provid
dr
v
deubel
formerli
institut
pasteur
pari
franc
cultur
mosquito
cell
aed
albopictu
american
type
cultur
collect
atcc
dulbecco
modifi
eagl
medium
dmem
gibco
belgium
lglutamin
gibco
penicillin
uml
streptomycin
solut
gibco
non
essenti
amino
acid
gibco
hepe
foetal
bovin
serum
fb
integro
netherland
strain
kindli
provid
dr
clair
huang
center
diseas
control
prevent
usa
propag
cell
describ
cell
african
green
monkey
kidney
cell
maintain
high
glucos
lglutamineenrich
dmem
paa
fb
penicillin
uml
streptomycin
mous
macrophag
cell
maintain
dmem
supplement
fb
penicillin
uml
streptomycin
sodium
bicarbon
invitrogen
solut
mm
sodium
pyruv
gibco
green
monkey
kidney
cell
verob
cell
ecacc
denv
assay
atcc
yfv
assay
grown
minimum
essenti
medium
mem
gibco
supplement
fb
lglutamin
sodium
bicarbon
gibco
antivir
assay
perform
medium
fb
babi
hamster
kidney
cell
atcc
grown
dmem
supplement
fb
cultur
medium
fb
assay
medium
cell
harbor
subgenom
dengu
replicon
deriv
dengu
replicon
construct
antibiot
select
cassett
encod
puromycin
nacetyltransferas
pac
togeth
firefli
luciferas
express
cassett
insert
upstream
nonstructur
ns
gene
refer
bhkreppacluc
cell
bhkreppacluc
cell
cultur
parent
cell
except
puromycin
ad
cultur
medium
sigmaaldrich
belgium
puromycin
omit
cultur
medium
antivir
assay
construct
infecti
fulllength
dengu
viru
renilla
luciferas
express
cassett
translat
control
encephalomyocard
viru
intern
ribosom
entri
site
emcv
ire
insert
upstream
untransl
region
report
earlier
viru
refer
dengu
report
viru
yellow
fever
viru
yfv
vaccin
strain
aventi
pasteur
msd
belgium
passag
verob
cell
prepar
work
viru
stock
store
use
modoc
viru
modv
strain
atcc
propag
cell
work
use
infecti
jev
strain
tbev
strain
oshima
wnv
strain
carri
biosafeti
level
laboratori
batch
viral
inoculum
jev
tbev
wnv
prepar
cultur
viru
twice
vero
cell
mem
supplement
fb
mm
lglutamin
penicillinstreptomycin
final
cell
cultur
supernat
collect
frozen
mm
hepe
teicoplanin
analogu
figur
synthes
report
elsewher
ribavirin
virazol
rbv
purchas
icn
pharmaceut
costa
mesa
ca
verob
cell
seed
plate
becton
dikinson
labwar
franklin
lake
nj
densiti
cellswel
assay
medium
allow
adher
overnight
subsequ
compound
dilut
seri
ad
cultur
infect
ie
cell
cultur
infecti
dose
ngc
assay
medium
plate
incub
rel
humid
day
post
infect
pi
cultur
fix
ethanol
stain
methylen
blue
ribavirin
includ
assay
refer
compound
verob
cell
seed
plate
one
day
later
cultur
medium
replac
assay
medium
contain
serial
dilut
compound
viru
inoculum
either
ngc
modv
follow
hour
incub
period
cell
monolay
wash
time
assay
medium
remov
nonadsorb
viru
cultur
incub
day
presenc
inhibitor
supernat
harvest
viral
rna
load
determin
realtim
quantit
rtpcr
effect
concentr
defin
compound
concentr
requir
inhibit
viral
rna
replic
determin
use
logarithm
interpol
ribavirin
includ
refer
compound
antivir
assay
jev
tbev
wnv
carri
verob
cell
plate
cellswel
briefli
cell
cultur
mem
supplement
fb
mm
lglutamin
penicillinstreptomycin
one
day
seed
cell
infect
viral
inoculum
multipl
infect
either
presenc
absenc
follow
incub
min
cultur
wash
twice
hank
balanc
salt
solut
hbss
ml
fresh
medium
either
supplement
compound
ad
well
cell
incub
medium
compound
refresh
day
pi
variou
time
point
pi
supernat
harvest
store
later
quantif
mean
rtpcr
potenti
cytotoxiccytostat
effect
compound
evalu
uninfect
cell
mean
mtspm
method
describ
earlier
cytotox
concentr
ie
concentr
reduc
total
cell
number
calcul
use
logarithm
interpol
rna
isol
supernat
nucleospin
rna
viru
kit
machereynagel
germani
describ
manufactur
primer
probe
sequenc
describ
earlier
taqman
probe
fluoresc
label
fam
end
report
dye
minor
groov
binder
mgb
end
quencher
onestep
quantit
rtpcr
perform
total
volum
contain
master
mix
eurogentec
belgium
forward
primer
revers
primer
probe
revers
transcriptas
eurogentec
sampl
rtpcr
perform
use
abi
fast
realtim
pcr
system
appli
biosystem
branchburg
nj
use
follow
condit
min
min
follow
cycl
min
data
analyz
use
abi
prism
sd
softwar
version
appli
biosystem
absolut
quantif
standard
curv
gener
use
dilut
templat
prepar
known
concentr
verob
cell
seed
chamber
slide
labtek
ii
nunc
germani
densiti
cellswel
hour
later
cell
infect
ngc
presenc
absenc
viru
inoculum
remov
hour
cell
wash
incub
presenc
compound
hour
cell
stain
antidengu
e
protein
antibodi
ab
clone
millipor
billerica
antiyfv
ab
secondari
ab
alexa
fluor
millipor
follow
dapi
stain
cultur
visual
use
confoc
laser
scan
microscop
lcsm
leica
microsystem
germani
one
day
prior
infect
cell
seed
tissu
culturetr
white
view
plate
perkin
elmer
boston
next
day
cell
infect
pfuwel
dengu
report
viru
one
hour
viru
inoculum
replac
assay
medium
concentr
ad
assay
medium
hour
infect
ie
togeth
viru
hour
post
infect
luciferas
activ
measur
hour
pi
use
renilla
luciferas
assay
system
promega
netherland
luciferas
activ
treat
infect
cell
compar
untreat
infect
cell
experi
yfv
confluent
verob
cell
plate
iwaki
asahi
techno
glass
japan
treat
infect
yfv
similar
way
done
denv
hour
pi
intracellular
rna
isol
use
rneasi
minikit
qiagen
rna
level
quantifi
use
rtqpcr
addit
elabor
assay
perform
yfv
compound
ad
cell
cultur
everi
minut
begin
minut
infect
minut
infect
verob
cell
seed
chamber
slide
nunc
densiti
cellswel
next
day
cell
infect
ngc
one
hour
later
inoculum
replac
assay
medium
concentr
ad
assay
medium
hour
infect
togeth
viru
hour
post
infect
cell
stain
describ
bhkreppacluc
cell
seed
densiti
cellswel
tissu
culturetr
white
view
plate
perkinelm
next
day
medium
replac
twofold
serial
dilut
hour
luciferas
activ
measur
use
luciferas
assay
system
accord
manufactur
protocol
promega
luciferas
activ
compar
untreat
replicon
cell
cytotox
effect
compound
bhkreppacluc
cell
evalu
parallel
cultur
use
mtspm
assay
ribavirin
includ
compar
reason
replic
inhibitor
inhibitori
effect
compound
luciferas
activ
adjust
inhibitori
effect
cell
prolifer
undilut
stock
pfu
incub
presenc
absenc
presenc
absenc
rnase
promega
one
hour
rnase
inactiv
mgml
proteinas
k
promega
viral
rna
isol
use
nucleospin
kit
filter
servic
sampl
subject
rtpcr
gel
electrophoresi
posit
control
consist
viru
incub
mgml
proteinas
k
enzym
inactiv
hour
mm
phenylmethanesulfonyl
fluorid
pmsf
sigmaaldrich
minut
rnase
ad
follow
hour
incub
rna
isol
sampl
analyz
lipophil
fluoresc
probe
salt
molecular
probe
eugen
use
label
viral
membran
viru
particl
previous
describ
brief
wild
type
viru
propag
cell
harvest
day
pi
subsequ
viru
purifi
potassiumtartr
densiti
gradient
wtvol
ultracentrifug
beckman
type
rotor
h
g
store
viru
prepar
analyz
respect
infecti
titer
pfu
number
genomecontain
particl
gcp
describ
label
tartrat
clear
use
kda
filter
devic
millipor
netherland
vortex
approxim
gcp
viru
equival
pfu
mix
nmol
dissolv
dimethyl
sulfoxid
dmso
end
concentr
dmso
remov
unbound
dye
didlabel
viru
filter
sephadex
fine
pharmacia
uppsala
sweden
column
prepar
glass
pasteur
pipett
differ
fraction
collect
store
use
within
day
cell
seed
labtek
ii
chamber
coverglass
nunc
well
confluent
day
infect
prior
bind
assay
cell
incub
min
subsequ
didlabel
denv
ad
presenc
absenc
dmso
control
incub
continu
h
unbound
viru
remov
gentli
wash
cell
three
time
cold
phenol
redfre
mem
subsequ
cold
phenol
redfre
mem
contain
glucos
glucos
oxidas
solut
glox
ad
cell
microscop
analysi
done
describ
glox
compos
glucos
oxidas
type
vii
aspergillu
niger
sigma
aldrich
solut
prepar
pb
catalas
beef
liver
roch
fusion
assay
experiment
setup
use
except
cell
kept
experi
ammonium
chlorid
mm
chlorpromazin
use
neg
control
fusion
assay
microscopi
analysi
done
take
snapshot
randomli
select
field
use
differenti
interfer
contrast
dic
channel
dic
imag
taken
field
make
sure
visual
didparticl
bound
cell
lie
empti
space
attach
cell
didlabel
virus
detect
epifluoresc
microscopi
leica
biosystem
instrument
use
laser
fluoresc
emiss
collect
oilimmers
object
numer
apertur
leica
microsystem
imag
use
em
ccd
camera
hamamatsu
thermostat
stage
object
heater
use
keep
temperatur
fusion
assay
acquir
imag
process
analyz
imagej
use
inhous
macro
bind
assay
total
number
bound
didparticl
count
extent
membran
fusion
analyz
measur
total
fluoresc
signal
per
imag
field
minut
post
infect
quantit
result
neg
control
fusion
assay
taken
background
henc
subtract
total
fluoresc
result
posit
control
treatment
viru
virusantibodi
complex
ad
cell
moi
presenc
absenc
serial
twofold
dilut
incub
h
anti
antibodi
gener
provid
diamond
washington
univers
st
loui
usa
cell
wash
pb
new
media
ad
hpi
cell
fix
stain
fac
analysi
previous
describ
number
infect
cell
determin
use
anti
monoclon
antibodi
millipor
virusantibodi
complex
format
viru
particl
incub
h
murin
anti
antibodi
ngml
cell
cultur
medium
contain
fb
prior
addit
cell
defin
accord
percentag
infect
inhibit
rel
posit
control
cytotox
effect
observ
concentr
evalu
